RECRUITING

New Strategies to Enhance Smoking Cessation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study goal is to get feedback on ways researchers can communicate complex research findings on smoking cessation to better inform patients' decisions to use medication and/or quit smoking. This will help researchers and clinicians to provide effective, easy-to-implement treatments designed to address tobacco-related health disparities in Black and other racial/ethnic subgroups. It will also help improve health literacy to change misperceptions and mistrust on uptake of varenicline and other medication for quitting smoking. A professionally made video will explain research findings relevant for varenicline's mechanisms and outcomes relative to other treatment options. There are 2 parts to this study: * Part 1: Focus Group to help develop the educational tool intervention * Part 2: Randomized portion of study. In this part of the study, participants will be randomized (like flip of coin) to take part in receive the experimental educational intervention or usual methods to help stop smoking. Participants in either arm can choose to receive varenicline and it will be provided as part of study.

Official Title

Uptake of Varenicline and Strategies for Enhanced Engagement in Treatment for Smoking Cessation

Quick Facts

Study Start:2025-04-24
Study Completion:2030-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06751927

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients must smoke at least 10 cigarettes/day and do not currently use a smoking cessation medication.
  2. * Ages 18-75.
  3. * Agree to complete surveys and measures within study.
  4. * Ability to understand English and the willingness to sign a written informed consent document.
  1. * Patients who are receiving any other smoking cessation medications.
  2. * Patients who are pregnant and/or lactating.
  3. * Patients with psychiatric contraindications that can prevent adherence to protocol or use of intervention tools in study. For inclusivity on trial, psychiatric contraindications and ability for patient to participate in trial will be assessed on an individual basis by study investigator.
  4. * Patients who have a contraindication with varenicline.

Contacts and Locations

Study Contact

Clinical Trials Intake
CONTACT
1-855-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator

Andrea C. King
PRINCIPAL_INVESTIGATOR
University of Chicago

Study Locations (Sites)

University of Chicago
Chicago, Illinois, 60637
United States

Collaborators and Investigators

Sponsor: University of Chicago

  • Andrea C. King, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-24
Study Completion Date2030-12

Study Record Updates

Study Start Date2025-04-24
Study Completion Date2030-12

Terms related to this study

Additional Relevant MeSH Terms

  • Smoking Cessation